MIRA Profile
MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on advancing novel therapies for neurological and psychological conditions. The company's primary emphasis is on the development and commercialization of a new synthetic analog of tetrahydrocannabinol (THC), specifically designed to address symptoms associated with anxiety and cognitive decline in adult patients, particularly those experiencing early-stage dementia. This innovative approach aims to leverage the therapeutic potential of cannabinoids to offer new treatment options for these challenging conditions.
MIRA Pharmaceuticals is developing MIRA1a, a synthetic cannabinoid analog that targets both cannabinoid type 1 (CB1) and type 2 (CB2) receptors. This targeted approach is designed to modulate the endocannabinoid system, potentially alleviating anxiety and chronic pain. The company's research is centered on exploring the efficacy and safety of MIRA1a in managing symptoms related to anxiety disorders and chronic pain, with a focus on enhancing the quality of life for patients who have limited options for effective treatment.
Originally known as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals rebranded to its current name to reflect its broader strategic focus and commitment to advancing cannabinoid-based therapies. Since its incorporation in 2020, the company has been dedicated to pushing the boundaries of cannabinoid science and developing therapeutics that address significant unmet medical needs. Headquartered in Baltimore, Maryland, MIRA Pharmaceuticals is positioned at the forefront of biopharmaceutical innovation in the cannabinoid sector.
The company’s ongoing research and development efforts aim to validate the therapeutic potential of synthetic cannabinoids in treating complex neurological and psychological conditions. By advancing MIRA1a through clinical trials and exploring additional applications, MIRA Pharmaceuticals seeks to establish itself as a leader in the field of cannabinoid-based medicine. The company’s commitment to scientific excellence and patient-centered solutions underscores its role in shaping the future of biopharmaceutical interventions for anxiety and cognitive decline.
|
